since the compliance of the patients with the single dose regimen was very good and the efficacy the same in reducing plasma prl and controlling the clinical manifestations with a lower rate of side effects , we suggest to extend this regimen to all patients with hyperprolactinemia treated with bromocriptine after successful reduction of plasma prl levels is obtained .
C0020514
hyperprolactinemia
C0006230
bromocriptine